• LAST PRICE
    1.3150
  • TODAY'S CHANGE (%)
    Trending Down-0.0650 (-4.7101%)
  • Bid / Lots
    1.3000/ 18
  • Ask / Lots
    1.3300/ 1
  • Open / Previous Close
    1.3950 / 1.3800
  • Day Range
    Low 1.2900
    High 1.3950
  • 52 Week Range
    Low 1.2500
    High 8.6799
  • Volume
    14,611
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 1.38
TimeVolumeIMMX
09:32 ET2001.395
09:54 ET4431.3511
09:57 ET13961.35
10:01 ET10001.3773
10:12 ET2211.32
10:51 ET3001.33
11:02 ET1001.33
11:13 ET4991.33
11:20 ET3001.34
11:26 ET1001.33
11:31 ET2751.3343
11:54 ET8211.33
12:00 ET2251.33
12:25 ET1001.3
12:45 ET1001.29
12:56 ET5001.3
01:15 ET1001.3134
01:21 ET14001.32
01:26 ET7001.32
01:32 ET12371.33
01:46 ET1001.33
01:55 ET1001.315
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesIMMX
Immix Biopharma Inc
18.9M
-0.4x
---
United StatesCABA
Cabaletta Bio Inc
18.9M
-0.4x
---
United StatesALRN
Aileron Therapeutics Inc
18.8M
-0.8x
---
United StatesONCS
OncoSec Medical Inc
19.2M
-0.5x
---
United StatesMNPR
Monopar Therapeutics Inc
19.3M
-2.1x
---
United StatesNDRA
ENDRA Life Sciences Inc
19.3M
-1.3x
---
As of 2022-10-07

Company Information

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing a class of Tissue-Specific Therapeutics (TSTx) in oncology and inflammation. Its lead asset, IMX-110, is in Phase Ib/IIa clinical trials for solid tumors in the United States and Australia. IMX-110 is a negatively-charged TSTx that simultaneously disables resistance pathways with a poly-kinase inhibitor and induces tumor cell death with an apoptosis inducer controlling tumor micro-environment (TME) normalization technology. IMX-110, which is in clinical trials for solid tumors in the United States and Australia. The Company’s System Multi-Action RegulaTors SMARxT Tissue-Specific platform produces drugs that accumulate at intended therapeutic sites at 3-5 times the rate of conventional medicines. Its Immune Normalization Technology is used for inflammatory bowel disease with GLUT1 antibody biomarker targeting coupled with polyphenol poly-kinase inhibitor/apoptosis inducer.

Contact Information

Headquarters
11400 West Olympic Blvd., Suite 200LOS ANGELES, CA, United States 90064
Phone
310-651-8041
Fax
---

Executives

Chairman of the Board, Chief Executive Officer
Ilya Rachman
Scientific Co-Founder
Vladimir Torchilin
Chief Financial Officer, Director
Gabriel Morris
Head of Chemistry, Manufacturing, and Control
Nandan Oza
Acting Chief Medical Officer and Head of Clinical Development
Graham Ross

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$18.9M
Revenue (TTM)
$0.00
Shares Outstanding
13.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-3.43
Book Value
$1.36
P/E Ratio
-0.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.